Expect more tuck-in M&A, portfolio pruning in medtech, execs say

Expect more tuck-in M&A, portfolio pruning in medtech, execs say is a pharma and life sciences industry update from MedTech Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Susan Kelly · 2026-10-21

As medical device makers face “finite” capital, portfolio reshaping will likely remain a focus in the sector.

Source: MedTech Dive